BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17625604)

  • 21. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
    Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
    Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
    Basso K; Dalla-Favera R
    Adv Immunol; 2010; 105():193-210. PubMed ID: 20510734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging drugs for diffuse large B-cell lymphoma.
    Mondello P; Younes A
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic lesions in diffuse large B-cell lymphomas.
    Testoni M; Zucca E; Young KH; Bertoni F
    Ann Oncol; 2015 Jun; 26(6):1069-1080. PubMed ID: 25605746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
    Sehn LH; Gascoyne RD
    Blood; 2015 Jan; 125(1):22-32. PubMed ID: 25499448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.
    Iqbal J; Shen Y; Huang X; Liu Y; Wake L; Liu C; Deffenbacher K; Lachel CM; Wang C; Rohr J; Guo S; Smith LM; Wright G; Bhagavathi S; Dybkaer K; Fu K; Greiner TC; Vose JM; Jaffe E; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Armitage JO; Weisenburger DD; Staudt LM; Gascoyne RD; McKeithan TW; Chan WC
    Blood; 2015 Feb; 125(7):1137-45. PubMed ID: 25498913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
    Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.
    Carbone A; Gloghini A; Kwong YL; Younes A
    Ann Hematol; 2014 Aug; 93(8):1263-77. PubMed ID: 24870942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
    Roschewski M; Staudt LM; Wilson WH
    Nat Rev Clin Oncol; 2014 Jan; 11(1):12-23. PubMed ID: 24217204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
    Clozel T; Yang S; Elstrom RL; Tam W; Martin P; Kormaksson M; Banerjee S; Vasanthakumar A; Culjkovic B; Scott DW; Wyman S; Leser M; Shaknovich R; Chadburn A; Tabbo F; Godley LA; Gascoyne RD; Borden KL; Inghirami G; Leonard JP; Melnick A; Cerchietti L
    Cancer Discov; 2013 Sep; 3(9):1002-19. PubMed ID: 23955273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genetic basis of diffuse large B-cell lymphoma.
    Pasqualucci L
    Curr Opin Hematol; 2013 Jul; 20(4):336-44. PubMed ID: 23673341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
    Morin RD; Mendez-Lago M; Mungall AJ; Goya R; Mungall KL; Corbett RD; Johnson NA; Severson TM; Chiu R; Field M; Jackman S; Krzywinski M; Scott DW; Trinh DL; Tamura-Wells J; Li S; Firme MR; Rogic S; Griffith M; Chan S; Yakovenko O; Meyer IM; Zhao EY; Smailus D; Moksa M; Chittaranjan S; Rimsza L; Brooks-Wilson A; Spinelli JJ; Ben-Neriah S; Meissner B; Woolcock B; Boyle M; McDonald H; Tam A; Zhao Y; Delaney A; Zeng T; Tse K; Butterfield Y; Birol I; Holt R; Schein J; Horsman DE; Moore R; Jones SJ; Connors JM; Hirst M; Gascoyne RD; Marra MA
    Nature; 2011 Jul; 476(7360):298-303. PubMed ID: 21796119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
    Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
    Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
    Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.